Cevian's Growing Stake and a Sharp Short Cover Set Up Smith & Nephew's Thursday Print

SNN drops its third-quarter numbers on Thursday with two unusually concrete data points framing the result: a short position that collapsed nearly 19% in a week, a move that sits two standard deviations below the company's typical weekly change, and an activist investor who has spent all year building a 14% stake and is now the largest shareholder on record.

The short cover is the most immediately measurable signal. ORTEX estimates put short interest at roughly 4.17 million shares as of October 30, down from around 5.1 million a week earlier. That single-week drop is the sharpest in the 30-day dataset. What it means in practical terms: bears who had held positions through the summer were trimming ahead of the release, not adding. Cost to borrow tells a different story, rising about 8% over the past week to just under 10%, which suggests the shares that remain short are not finding it easier to stay short. Availability in the lending pool has tightened sharply too, falling by more than half in a week to 28%, meaning roughly one share is available for every three already on loan. The put/call ratio at 0.20 is well below its 20-day average of 0.32, placing options sentiment more than a standard deviation to the bullish side, a clear shift from late September when the PCR touched nearly 2.0. The stock itself has recovered 14% over the past month to $30.24, with a 1.8% gain on Monday adding to the run.

The central tension for Thursday is whether operational progress can satisfy a shareholder base that now includes an outspoken activist. Cevian Capital has filed eight Schedule 13D amendments since first disclosing in December 2024, and its most recent filing on July 27 lifted its stake to 14.18%, up from 13.09%. That makes Cevian the largest single holder, ahead of BlackRock's 9.5% passive position. Cevian's presence on a 13D, rather than a passive 13G, means the firm has declared an intent to engage on strategy or capital allocation, not just hold for index exposure. The bull case centres on the orthopedic reconstruction recovery, where CORI placements have driven underlying growth, and management's stated expectation of margin improvement in the second half. The bear case is harder to dismiss given two downgrades in early August: JP Morgan moved to Neutral from Overweight and Barclays went to Underweight from Equal-Weight, both within a day of the prior earnings release, which itself sent the shares down more than 6% in a single session and roughly the same over the following week. Neither firm gave a revised price target at the time. With the stock now back at $30.24, Canaccord Genuity's Hold target of $30, set in May, is effectively at the money, while Bernstein's Market Perform target of $37.50 suggests there is a meaningful gap to close if execution improves. The consensus price target of $47.88 in the snapshot dates to January 2021 and should be disregarded entirely as a reference point.

The EV/EBITDA multiple has edged up to 16.3x over the past month as the price recovered, and the earnings yield factor ranks in the 72nd percentile, giving the stock a reasonable value case by sector standards. The short score of 53.4 is middling and has drifted slightly lower over the past two weeks, consistent with the short cover in progress. Together, the positioning looks less like a crowded bear trade and more like a market that has reduced its explicit downside bets without fully committing to the recovery.

Thursday's result will test whether the margin improvement that management guided toward for the second half has arrived in the numbers, and whether China volumes have stabilised enough to keep the full-year growth framework intact.